Literature DB >> 17614294

Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients.

Dirk Rades1, Steven E Schild, Radka Lohynska, Theo Veninga, Lukas J A Stalpers, Juergen Dunst.   

Abstract

BACKGROUND: Nonsmall cell lung cancer (NSCLC) patients with brain metastases usually receive whole-brain radiotherapy (WBRT). Most of these patients survive for only a few months. A short course of WBRT would be preferable to longer regimens if it could provide similar survival. This retrospective study of NSCLC patients compared longer treatment programs with short-course WBRT with 5 x 4 Gy given during 5 days.
METHODS: Data from 404 NSCLC patients treated with WBRT for brain metastases were retrospectively analyzed. The 140 patients who received 5 x 4 Gy given in 5 days were compared for survival with 264 patients who received either 10 x 3 Gy given in 2 weeks or 20 x 2 Gy given in 4 weeks. Seven further potential prognostic factors were investigated for survival including age, sex, Karnofsky performance score (KPS), number of brain metastases, extracranial metastases, interval from tumor diagnosis to WBRT, and RPA (recursive partitioning analysis) class.
RESULTS: The WBRT regimen was not associated with survival (P = .55). On multivariate analysis, age < 60 years (vs > or =60 years, P = .020), KPS > or =70 (vs KPS < 70, P < .001), interval from tumor diagnosis to WBRT > 12 months (vs < or =12 months, P = .007), no extracranial metastases (P < .001), and RPA class 1 (vs RPA class 2 vs RPA class 3, P = .007) were significantly associated with improved survival.
CONCLUSIONS: Short-course WBRT with 5 x 4 Gy appeared preferable for most NSCLC patients, as it was associated with survival similar to longer WBRT programs, and the short course was less time consuming.

Entities:  

Mesh:

Year:  2007        PMID: 17614294     DOI: 10.1002/cncr.22877

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Lung cancer: Best supportive care - a reasonable option for patients with brain metastases?

Authors:  Dirk Rades; Steven E Schild
Journal:  Nat Rev Clin Oncol       Date:  2016-11-08       Impact factor: 66.675

2.  Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases.

Authors:  Carsten Nieder; Anca L Grosu; Kirsten Marienhagen; Nicolaus H Andratschke; Hans Geinitz
Journal:  Med Oncol       Date:  2012-04-01       Impact factor: 3.064

3.  Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC).

Authors:  Dirk Rades; Roger Nadrowitz; Inga Buchmann; Peter Hunold; Frank Noack; Steven E Schild; Birgit Meller
Journal:  Strahlenther Onkol       Date:  2010-07-29       Impact factor: 3.621

Review 4.  Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.

Authors:  Elisa De Carlo; Elisa Bertoli; Alessandro Del Conte; Brigida Stanzione; Eleonora Berto; Alberto Revelant; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

Review 5.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

6.  Prognostic factors analysis in EGFR mutation-positive non-small cell lung cancer with brain metastases treated with whole brain-radiotherapy and EGFR-tyrosine kinase inhibitors.

Authors:  Hangping Wei; Meng Su; Ruifang Lin; Huifang Li; Changlin Zou
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

7.  Brain metastasis from non-small cell lung cancer (NSCLC): prognostic importance of the number of involved extracranial organs.

Authors:  L Gerdan; B Segedin; V Nagy; M T Khoa; N T Trang; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-10-09       Impact factor: 3.621

8.  Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.

Authors:  Jing Wang; Zhiyan Liu; Qingsong Pang; Tian Zhang; Xi Chen; Puchun Er; Yuwen Wang; Ping Wang; Jun Wang
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

Review 9.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

10.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.